How do you manage hypoxia induced by belzutifan?

Hypoxia is an on-target adverse effect (AE) of belzutifan. All-grade hypoxia was reported in 14.5% of patients (10.5 %, grade 3 and above) in the LITESPARK-005 trial (Choueiri et al., PMID 39167807). Discontinuation of belzutifan due to hypoxia was <1%. Of note, patients with hypoxia (<92% of oxygen...